01 May 1998
Evaluation of cross-reactive antiplatelet antibodies in whole blood by means of flow cytometry - limitations and pitfalls
Magdalena Boncler, Cezary Watała, Jacek GolańskiMed Sci Monit 1998; 4(3): BR413-418 :: ID: 502397
Abstract
Platelet surface membrane alloantigens are believed to be the cause of alloimmunization phenomena following blood transfusions or due to antigenic immunocompetence between mother and fetus encountered in pregnant women. Under such conditions of incompatibility, alloimmunization can result in the resistance of donor platelets following blood transfusions. The advantage of flow cytometry in determining the occurrence of platelet alloantibodies (in comparison to other methods, like MAIPA) is that it is easy to perform with small aliquots of whole blood, the obtained results can be quantitatively evaluated and stored for later comparisons, and the technique can be also used in cases when platelet counts are low, such as in thrombocytopenias. The methods principle is that more alloantigenic or donor-incompatible platelets bind with more immunoglobulins in the recipient's plasma. Blood samples were incubated with FITC-labelled F(ab')2 antibodies, directed against IgG, adsorbed on the platelet's surface. Higher incompatibility resulted in the enhanced binding of F(ab')2-FITC antibodies. The attributed FITC-derived fluorescence, reflecting the extent to which platelets were coated with specific immunoglobulins, intensified along with the increasing immunoincompetence of the recipient's platelets and donor's plasma. Control values of the fluorescence ratio (FR = RFIF(ab')2-FITC: RFIIgGFITC) fluctuated between 1.08-1.77 (min-max), which corresponded to the normal range (mean±1SD) of 1.015-1.835. In other cases, the FR values for AB0-incompatible 'pairs' fluctuated between 1.75-3.26 which corresponded to the normal range (mean±1SD) of 1.606-3.464. The increase of FR above 1.75-1.85 may suggest a higher risk for serologic incompatibility and considerably downgrade successful blood transfusions.
Keywords: platelet surface antigens, platelet-reactive antibodies, platelet serology, Alloimmunization, alloantigenicity, Immunocompetence
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952